Clinical Trials Logo

Lymphoma, Extranodal NK-T-Cell clinical trials

View clinical trials related to Lymphoma, Extranodal NK-T-Cell.

Filter by:

NCT ID: NCT04554511 Recruiting - Clinical trials for Extranodal NK/T-cell Lymphoma

Prognostic Nomogram of Extranodal NK/T-cell Lymphoma

Start date: August 28, 2020
Phase:
Study type: Observational

This study aims to evaluate prognostic factors for overall survival and explore risk progression-free survival in ENKTL, and establish a prognostic predictive nomogram for ENKTL patients.

NCT ID: NCT04526834 Active, not recruiting - Clinical trials for Diffuse Large B Cell Lymphoma

Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma

CERTAIN
Start date: September 8, 2021
Phase: Phase 1
Study type: Interventional

This is a phase 1 study to evaluate safety and dose-limiting toxicity of autologous CD30.CAR-T in subjects with relapsed or refractory CD30+ Non-Hodgkin Lymphoma

NCT ID: NCT04509466 Terminated - Clinical trials for Extranodal NK/T-cell Lymphoma, Nasal Type

Clinical Study of Liposomal Mitoxantrone Hydrochloride Injection Combined With Pegaspargase in the Treatment of NKTCL

Start date: September 15, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multicentre, open-label, single-arm, phase I/II clinical study to evaluate the safety, efficacy and pharmacokinetics of liposomal mitoxantrone hydrochloride in combination with pegaspargase in patients with extranodal natural killer/T-cell lymphoma, nasal type (NKTCL).

NCT ID: NCT04484506 Recruiting - Clinical trials for NK/T Cell Lymphoma Nos

Pegaspargase-COEP Chemotherapy Combined With Radiotherapy for Extra-nodal NK/T Cell Lymphoma

Start date: October 20, 2011
Phase: Phase 2
Study type: Interventional

The optimal first-line treatment for extra-nodal NK/T-cell lymphoma (ENKTL) has not been well-defined. This phase II study aimed to evaluate the efficacy and safety of pegaspargase, cyclophosphamide, vincristine, etoposide and prednisone (COEPL) regimen combined with radiotherapy for patients with newly diagnosed ENKTL.

NCT ID: NCT04417166 Recruiting - Clinical trials for Lymphoma, Extranodal NK-T-Cell

Pembrolizumab and Radiotherapy for Patients With NK/T Cell Lymphoma

Start date: February 11, 2022
Phase: Phase 2
Study type: Interventional

Aim of the trial is to evaluate the activity and tolerability of the anti PD1 agent Pembrolizumab in combination with RadioTherapy for the initial treatment of previously untreated patients with limited stage NK/T cell lymphoma who are not eligible to chemotherapy. It is planned to enroll 30 patients in chinese sites. All eligible patients will be treated with standard radiotherapy and concurrent pembrolizumab administered intravenously every 3 weeks. After 6 cycles of pembrolizumab patients with complete remission, partial response and stable disease will continue with pembrolizumab maintenance up to 2 years. Patients will be followed up to 4 years from treatment start.

NCT ID: NCT04414163 Active, not recruiting - Clinical trials for Extranodal NK/T-cell Lymphoma, Nasal Type

A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type

Start date: July 28, 2020
Phase: Phase 2
Study type: Interventional

This is a phase 2, Open-label, to investigate the efficacy and safety of IMC-001 in patients with Relapsed or Refractory extranodal NK/T cell lymphoma, nasal type

NCT ID: NCT04405375 Recruiting - Clinical trials for Extranodal NK/T-cell Lymphoma, Nasal Type

GPED Regimen for Relapsed/Refractory or Advanced ENKTCL

Start date: March 21, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of gemcitabine, pegaspargase, etoposide, and dexamethasone (GPED) in the treatment of Relapsed/Refractory or advanced NK/T-cell lymphoma patients (ENKTCL).

NCT ID: NCT04338282 Not yet recruiting - Clinical trials for Extranodal NK/T-cell Lymphoma, Nasal Type

Maintenance Therapy With Anti-PD-1 Antibody for Patients With NK/T-cell Lymphoma

Start date: June 1, 2020
Phase: Phase 2
Study type: Interventional

For patients with NK/T-cell lymphoma, plasma EBV-DNA has been found to be a prognostic factor, and those with positive plasma EBV-DNA at the end of treatments are more likely to suffer from disease relapse. Thus, this study aims to evaluate the role of maintenance with anti-PD-1 antibody.

NCT ID: NCT04337593 Not yet recruiting - Clinical trials for Extranodal NK/T-cell Lymphoma

Combination of Basiliximab and Pegaspargase in the Treatment of ENKTCL

Start date: June 1, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Basiliximab in combination with pegaspargase in the treatment of relapsed/refractory NK/T-cell lymphoma.

NCT ID: NCT04279379 Recruiting - Clinical trials for Extranodal NK/T-cell Lymphoma

Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma

Start date: April 1, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Sintilimab in combination with decitabine in the treatment of Relapsed/Refractory or advanced NK/T-cell lymphoma patients